YolTech Therapeutics reported positive clinical data for YOLT-203, an in vivo gene editing therapy, demonstrating excellent safety and pharmacodynamic profiles in PH1 patients.
Intellia Therapeutics has initiated a pivotal Phase 3 trial (HAELO) of NTLA-2002 for hereditary angioedema, evaluating its ability to reduce HAE attacks through plasma kallikrein activity reduction.
YolTech Therapeutics has dosed the first two patients in a Phase 1 trial of YOLT-203, a novel in vivo CRISPR gene-editing therapy for primary hyperoxaluria type 1 (PH1).
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.